

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/026,993 12/19/2001		John M. Fevig	PH-7263	1186	
23914	7590	04/23/2003			
STEPHEN			EXAMINER		
PATENT DE	PARTMEN	UIBB COMPAN' NT	HABTE, KAHSAY		
P O BOX 40		3-4000	ART UNIT	PAPER NUMBER	
	,			1624	
				DATE MAILED: 04/23/2003	_

Please find below and/or attached an Office communication concerning this application or proceeding.

ï		Application N	lo.	Applicant(s)					
		10/026,993		FEVIG ET AL.	•				
	Office Action Summary	Examiner		Art Unit					
		Kahsay Habte		1624					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status	Decreasive to communication(s) filed on								
1)[]	Responsive to communication(s) filed on This action is <b>FINAL</b> . 2b)	 This action is no	n-final						
2a)□	<i>,</i> —			osecution as to th	ne merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims									
4)⊠ Claim(s) <u>1-28</u> is/are pending in the application.									
4a) Of the above claim(s) is/are withdrawn from consideration.									
	Claim(s) is/are allowed.								
6) Claim(s) is/are allowed.									
	7) Claim(s) is/are objected to.								
,	Claim(s) <u>1-28</u> are subject to restriction and/o	or election requir	ement.						
Application Papers									
9) 🔲 -	The specification is objected to by the Exami	iner.							
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12)☐ The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) ☐ All b) ☐ Some * c) ☐ None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
1)  Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s	5)		/ (PTO-413) Paper No Patent Application (PT					

Application/Control Number: 10/026,993

Art Unit: 1624

## **DETAILED ACTION**

## Restriction/Election

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-3 (in part), 4-7(in part), 11, 13 (in part) and 18-28 (in part), drawn to oxazepines or thiazepines (for example X = -CH2O-, -SCH2-, -O-CH2-, -CH2S-), classified in class 540, subclass 544.
  - II. Claims 1-3 (in part), 4-7 (in part), 13 (in part) and 18-28 (in part), drawn to azepines and diazepines (X = -NR10-CH2-, -NHC(=O)-, -C(=O)NH-, -CH2-NR10-, -CH2CH2-), classified in class 540, subclass 494, 556 and 579.
  - III. Claims 1-3 (in part), 4-7 (in part), 10, 13 (in part), 15-16 (in part) and 18-28 (in part), drawn to morpholines and thiomorpholines (X = -O- or -S-), classified in class 544, subclass 14 and 99.
  - IV. Claims 1-3 (in part) and 18-28 (in part), drawn to piperazines (X= -NR10-), classified in class 544, subclass 343.
  - V. Claims 1-3 (in part), 4-7 (in part), 8, 12, 13 (in part), 15-16 (in part), 17 and 18-28 (in part), drawn to fused piperidines (X = -CH2-), classified in class 546, subclass 66.
  - VI. Claims 1-3 (in part), 4-7 (in part), 9, and 18-28 (in part), drawn to pyrrolidines (X = a bond), classified in class 548, subclass 421.

The inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 10/026,993

Art Unit: 1624

Groups I-VI are directed to structurally dissimilar compounds such that the variable core created by the varying definitions of X in the compound formula (I) do not belong to the same recognized class of chemical compounds in the art, and references anticipating one invention, would not render obvious the others. Group I that are drawn to oxazepines and thiazepines) 7-membered ring with nitrogen and oxygen or 7membered ring with sulfur and nitrogen) that is not present in Groups II-VI. Group II (azepines and diazepines) are different from Groups II-VI, because they contain 1-2 nitrogens in the seven-membered ring. Group III is different from Groups I-II and Groups IV-VI, since it is drawn to morpholines and thiomorpholines (six-membered ring with N and O or N and S at 1,4-position) that is not present in Groups I-II and Groups IV-VI. Group IV is drawn to piperazines (2 nitrogens in a six-membered ring) that is not present in Groups I-III and V-VI. Group V is drawn to piperidines (one nitrogen in a sixmembered ring) and this feature is not present in Groups I-IV and VI. Group VI is drawn to pyrrolidines and is different from Groups I-V, since pyrrolidines (5-membered ring with one nitrogen) is not present in Groups I-V. Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support separate patents. The compounds differ significantly in chemical structures. One skilled in the art would not consider such diverse structure equivalents of each other. Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support separate patents. The compounds differ

Application/Control Number: 10/026,993

Art Unit: 1624

significantly in chemical structures. One skilled in the art would not consider such diverse structure equivalents of each other.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

A telephone call was made to Mr. Scott Larsen on April 7, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

## Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (703) 308-4717. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Kahsay Habte, Ph. D.

Examiner Art Unit 1624

KH April 21, 2003 Mark L. Berch
Primary Examiner

Art Unit 1624